Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.99B P/E - EPS this Y -58.90% Ern Qtrly Grth -
Income -36.01M Forward P/E -39.88 EPS next Y -53.40% 50D Avg Chg 38.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 163.00%
Dividend N/A Price/Book 53.90 EPS next 5Y - 52W High Chg -9.00%
Recommedations 1.70 Quick Ratio 51.38 Shares Outstanding 62.87M 52W Low Chg 1,021.00%
Insider Own 9.42% ROA -11.21% Shares Float 23.47M Beta 1.19
Inst Own 96.68% ROE -15.14% Shares Shorted/Prior 7.26M/7M Price 57.83
Gross Margin - Profit Margin - Avg. Volume 759,377 Target Price 71.00
Oper. Margin - Earnings Date May 12 Volume 411,423 Change -0.03%
About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics News
04/10/24 MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
03/15/24 MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business
03/11/24 MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
03/10/24 MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
03/04/24 MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
03/01/24 Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX)
02/29/24 MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
02/26/24 MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
02/20/24 Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics
01/11/24 Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade
01/10/24 Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?
12/22/23 CFO Matthias Bodenstedt Sells 100,000 Shares of MoonLake Immunotherapeutics
11/14/23 MoonLake Immunotherapeutics (MLTX) Posts Q3 2023 Results: Clinical Progress Amid Controlled Expenses
11/14/23 MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
04:03 PM Why Former Highflier MoonLake Plummeted 29% After A Recent Run
11/05/23 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
10/26/23 12 Best Performing NASDAQ Stocks in 2023
10/20/23 12 Best Performing Biotech Stocks in 2023
10/16/23 MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst
10/16/23 Why Top-Notch MoonLake Surged 11% And Almost Broke Out
MLTX Chatroom

User Image BioRich Posted - 3 days ago

$MLTX nice pre-market movement. $ARVN solid week. $IBRX on absolute heater. Wish I never sold, especially because I don't see this coming back. $SRPT is a lottery ticket ready to be cashed within the next two months 175$ PT for this darling on FDA label expansion approval. Cheers!

User Image BioRich Posted - 4 days ago

$ADXN $OCGN $NWGL and $MLTX the pain has set in, time to feel the gain. These are all poised in great position to average down and turn profits. Cheers!

User Image BrahmaBear Posted - 04/22/24

$MLTX where are we going here?

User Image frontiere Posted - 04/19/24

$SLRN Accelyrin ref=$4.96 long starter with partial stop-loss below 4.8 in case it’s not a bottom… +pending more due dil EOY cash 721 add in 30M refund from CRO =$751M ➔>$200m negative EV (though annual cash burn almost half of cash on hand). busted IPO, a long saga of weirdness, but IL-17a inhibitor and tons of cash. HS Phase 3 in 2H24 Comp $MLTX Moonlake positive EV=~$2.1B ⁉️ + comp $VRDN Viridian positive EV=~+300m after Jan financing — whose data they dunk on in their latest deck.

User Image Okadarlan Posted - 04/18/24

$MLTX -11 @Racehorsetrainer

User Image BioRich Posted - 04/17/24

@WhoIsFrancois @User123321 most definitely. I've taken the approach in my recent purchases $ADXN $MLTX $ARVN $ARRNF and then $VNDA today that my focus is a realistic PT based on management, Financials, timing (e.g., earnings, PRs, Presentations, etc.), price and volume action, and any other intriguing factors such as current, past, and future interactions with FDA.

User Image BioRich Posted - 04/17/24

$VNDA it's ok to buy at a perceived premium for the day if you have conviction of long-term growth. Feel the same way about $TERN $ADXN $MLTX and $SRPT

User Image CH_Expat Posted - 04/12/24

$MLTX On watch for a re-entry at around 39.

User Image Wizardstock Posted - 04/12/24

$MLTX damn must be selling for options expiring next week

User Image BioRich Posted - 04/12/24

$MRK hoping to finish strong and hope they acquire $TERN $TRIV or $MLTX to expand their already robust portfolio.

User Image BioRich Posted - 04/11/24

$MLTX bought the news. This is a big deal and future is definitely north of 100$. My Scwab account shows $47.99 already. We may have a runner. Bios and BOs are hot right now. $ALPN $MRNA and $PFE bring that money over here for a nice 2x.

User Image Wizardstock Posted - 04/11/24

$MLTX $100 PT 😎

User Image S_Franconi Posted - 04/10/24

$MLTX This has been on my list nearly a year. I've been in and out. Yesterday I read the presentation with attention paid to Page 98. Bought. Nice surprise this morning. Thank you, Moonlake.

User Image RonIsWrong Posted - 04/10/24

$MLTX MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

User Image DonCorleone77 Posted - 04/10/24

$MLTX MoonLake Immunotherapeutics enters three-year partnership with Komodo Health MoonLake Immunotherapeutics and Komodo Health announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake's nanobody-based therapy in hidradenitis suppurativa and active psoriatic arthritis, two underdiagnosed diseases with significant unmet patient needs. Through this multiyear technology partnership, MoonLake will utilize Komodo's Healthcare Map and platform technologies to enable data-driven decision making across its clinical operations, medical, marketing, and market access teams. Tino Anthamatten, VP Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: "We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors...."

User Image Stock_Titan Posted - 04/10/24

$MLTX MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions https://www.stocktitan.net/news/MLTX/moon-lake-immunotherapeutics-inks-three-year-technology-partnership-nn7kbr1ptfi0.html

User Image Wizardstock Posted - 04/09/24

$MLTX i want that pump to 60+ i’ll settle for 50+ 🤣

User Image StockConsultant Posted - 04/08/24

$MLTX MoonLake stock back to 46.24 support area, high trade quality, https://stockconsultant.com/?MLTX

User Image DubK Posted - 04/07/24

@SeaTownGreen @Bilosellhigher Well that could be one of two scenarios. Either NCI somehow fudged the numbers to show benefit in trial to benefit PDSB to which they owe nothing. Trial that was chosen for oral presentation at ASCO. Or it could be that this wouldn’t be the first time Merck KGAA walked away from a drug & it became wildly successful. U can look at $MLTX ($3B) mcap. Lead drug is ex Merck KGA drug, licensed out in April, 2021. Vera($2B mcap). Lead drug is ex Merck KGA licensed from them in Nov, 2020. I believe another company just got bought out for Billions and was also a ex Merck KGAA drug.

User Image Wizardstock Posted - 1 month ago

$MLTX looks prime for next week with their conference 😎

User Image Wizardstock Posted - 1 month ago

$MLTX pump it over 50 😎

User Image OoeyGooey Posted - 1 month ago

$MLTX 🤮 Not been loving this stock recently. Still holding in the low 50's and have set a TP of $60, hopefully patience will win out on this one.

User Image Wizardstock Posted - 1 month ago

$MLTX how low can it go

User Image erevnon Posted - 1 month ago

Goldman Sachs initiates coverage on MoonLake $MLTX at Neutral rating and a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image Wizardstock Posted - 1 month ago

$MLTX 2 rumor buyouts now its just a waiting game to become official

User Image MZoom Posted - 03/28/24

$MLTX Thank me LATER ! Buy Zone is $48.78 - $51.31 Stop Zone is $46.23 - $46.63 Target Zone is $73 - $78

User Image RonIsWrong Posted - 03/28/24

$MLTX Watching MoonLake Immunotherapeutics; Shares Spike Higher, Traders Circulate Comments From Betaville LFG!

User Image Wizardstock Posted - 03/28/24

$MLTX LFG!!!

User Image Followsuit7 Posted - 03/26/24

$MLTX well that was a shit close. Huge supply where we reversed

User Image Spizzle Posted - 03/24/24

$MLTX this has got to be the only space I have seen not go to complete shit, is it delayed or something special..... Anyone got some good links to read up on?

Analyst Ratings
HC Wainwright & Co. Buy Apr 23, 24
HC Wainwright & Co. Buy Apr 11, 24
Needham Buy Apr 9, 24
Goldman Sachs Neutral Apr 2, 24
Wedbush Outperform Mar 13, 24
Wedbush Outperform Mar 11, 24
HC Wainwright & Co. Buy Mar 11, 24
Needham Buy Mar 11, 24
HC Wainwright & Co. Buy Mar 4, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Chen Bihua 10% Owner 10% Owner Oct 02 Buy 57.31 293,212 16,803,980 8,435,312 10/04/23
Chen Bihua 10% Owner 10% Owner Jun 26 Buy 52.64 450,000 23,688,000 4,127,100 06/28/23
Chen Bihua 10% Owner 10% Owner Mar 20 Buy 20.64 827,100 17,071,344 3,677,100 03/22/23